Bactericidal Effect of Combinations of Antimicrobial Drugs and Antineoplastic Antibiotics Against Staphylococcus Aureus JOHN Y

Total Page:16

File Type:pdf, Size:1020Kb

Bactericidal Effect of Combinations of Antimicrobial Drugs and Antineoplastic Antibiotics Against Staphylococcus Aureus JOHN Y ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1979, p. 580-586 Vol. 15, No. 4 0066-4804/79/04-0580/07$02.00/0 Bactericidal Effect of Combinations of Antimicrobial Drugs and Antineoplastic Antibiotics Against Staphylococcus aureus JOHN Y. JACOBS,`* JACQUES MICHEL,2 AND THEODORE SACKS2 Departments ofPharmacy Services' and Clinical Microbiology,2 Hadassah University Hospital and Hebrew University-Hadassah Medical School, Jerusalem, Israel Received for publication 29 January 1979 Six antineoplastic antibiotics were tested against ten strains of Staphylococcus aureus. Four showed bacteriostatic and/or bactericidal activity against each of the ten strains, and two were only bacteriostatic for seven and nine strains, respectively. Using the cellophane transfer technique, combinations of these antineoplastic antibiotics with 16 antibacterial drugs were screened for combined bactericidal activity. Synergism or antagonism was demonstrated in about one- third of the combinations. Checkerboard titrations and killing curves confirmed these findings and indicated that the effective concentrations of the antibacterial agents were similar to those attainable in the serum after therapeutic doses of these drugs. Although the pharmacokinetics of the six antineoplastic antibiotics in humans are not fully known, at least one of them has a peak serum level corresponding to those values at which a bactericidal effect was produced in vitro. Synergism and antagonism between combi- fulfillment of the requirements for a Ph.D. de- nations of antibacterial antibiotics has been well gree.) documented. Little attention, however, has been paid to possible synergism and antagonism be- MATERIALS AND METHODS tween antibacterial drugs and antineoplastic Ten strains of S. aureus were examined. Of these, antibiotics. Most antineoplastic antibiotics have nine were strains isolated from pus, blood, or urine measurable antibacterial activity but are not cultures in the Department of Clinical Microbiology used to treat bacterial infections because of a of the Hadassah-Hebrew University Hospital. (The low therapeutic index. minimal bactericidal concentrations [MBC] ofpenicil- In 1967, Manten and Terra described lin G for two of these nine strains were 16 and 64 ug/ (13) ml, respectively, and for seven strains MBCs were 256 antagonism and indifference, but no synergism, iLg/ml or higher. Strain 10 was S. aureus [Oxford] between combinations of two antineoplastic NCTC 6571, a non-penicillinas producer. The MBC antibiotics, dactinomycin and mitomycin C, and of penicillin G was 1.0 pug/mL) Minimum inhibitory ampicillin and penicillin G when tested on Strep- concentrations/MBCs were determined by using serial tococcus pyogenes, Staphylococcus aureus, dilutions of both the antibacterial and the antineo- Escherichia coli, and Candida albicans. Since plastic drugs inoculated with an overnight culture of then, many new antimicrobial agents and anti- the organism to give a final concentration of 106 bac- neoplastics have been introduced into clinical teria per ml. use, but there has been no systematic study of Each of 16 antibacterial drugs was combined with or each of 6 antineoplastic antibiotics, all of which are in possible synergism antagonism between these routine clinical use, and the 96 combinations were two groups of agents. Such a study might be of screened against 10 strains of S. aureus, using the clinical importance and possible theoretical in- cellophane transfer technique (3) as modified by Cluzel terest. et al. (6). Most patients receiving antineoplastic drugs Full details of the technique have been reported are potential recipients of antibacterial therapy (15). Commercially available cellophane (PO 300,0.019 because of their increased susceptibility to infec- mm thick) was used for the tambours. The impreg- tions, and they frequently receive both types of nated strips were prepared by immersing strips of agents simultaneously. We therefore decided to Whatman no. 3 chromatographic paper in solutions of investigate a variety of combinations of antibac- the drugs shown in Table 1 and drying at 37°C. These concentrations of the antibacterial drugs have been terial and antineoplastic agents against a series previously described as giving suitable test diffusion of different bacteria. This paper reports the re- levels (5), but these authors did not examine the sults with strains of S. aureus. antineoplastic antibiotics. To select the concentrations (This work has been submitted to the Hebrew of antineoplastic antibiotics shown in Table 1, we University of Jerusalem by J. Y. J. in partial initially prepared several strips for each antineoplastic 580 VOL. 15, 1979 ANTIMICROBIAL AND ANTINEOPLASTIC COMBINATIONS 581 TABLE 1. Concentrations used to impregnate paper drug in combination by the MBC of the drug alone. strips for the cellophane transfer technique The total of the FBCs of the two drugs tested is the Drug Symbol Concn (pg/ml) FBC index (ZFBC). By analogy with criteria defined by the Study Group (17) for the index of fractional Antibacterial inhibitory concentrations, a ZFBC of <0.6, which is Ampicillin AM 500 equivalent to reducing the concentration of each agent Carbenicilin CN 2,000 in the mixture to one-fourth of its MBC, was classified Cephaloridine CD 500 as significant synergy. An FBC index of >1.3 was Chloramphenicol C 1,000 regarded as significant antagonism. Clindamycin CL 500 Seven examples of synergism or antagonism were Colistin CO 650 examined to follow the kinetic action of the drugs Erythromycin E 200 individually and in combination during 24 h, using Gentamicin GE 500 concentrations of each drug selected from checker- Kanamycin K 500 board titrations. One-tenth milliliter of a suitably di- Methicillin ME 1,000 luted culture (prepared as above) was added to 2 ml of Nalidixic acid NA 500 Trypticase soy broth containing the selected concen- Penicillin G P 50 trations of the drugs alone or in combination. The Rifampin R 10 tubes were incubated at 37°C, and samples were taken Streptomycin S 50q for viable counts at time intervals from 0 to 24 h. Tetracycline T 200 Vancomycin V 400 RESULTS Antineoplastic Bleomycin B 100 Table 2 shows the antibacterial activity de- Dactinomycin AD 50 tected by the cellophane transfer technique of Daunorubicin DN 200 the antineoplastic agents acting alone. On re- Doxorubicin DX 100 moval of the tambour from the antibiotic- Mithramycin MT 50 treated agar medium and its transfer to antibi- Mitomycin C MC 100 otic-free medium, growth occurred on the tam- bour where the drug had been bacteriostatic and not where it had been bactericidal. drug, using varying concentrations of the drug in the Dactinomycin was bacteriostatic and mito- impregnating solutions. The strip chosen for the tam- mycin C was bactericidal for all 10 strains. Dau- bour test was one that gave a zone of inhibition of 4 to norubicin was usually bactericidal, whereas its 5 mm with strains of S. aureus seeded on agar plates. 14-hydroxy derivative, doxorubicin, was more Care was taken to avoid "carryover" (5). Oxoid DST bacteriostatic. and mith- agar was used for the diffusion and transfer plates. frequently Bleomycin The inoculum contained approximately 106 organisms ramycin were either bacteriostatic or inactive. per ml and was obtained by dilution of an overnight Minimum inhibitory concentrations/MBCs of culture in Trypticase soy broth (Difco). All the results the antimicrobial drugs and the antineoplastic were classified as synergism, indifference, or antago- antibiotics, determined by the serial dilution nism by two of the authors independently, using pre- method, are shown in Table 3. viously published criteria (4, 10). Doubtful results were Ninety-six combinations were tested by the duplicated or even triplicated. On the basis of the cellophane transfer technique on each strain, cellophane transfer results, 11 combinations were cho- and the synergistic and antagonistic results are sen from groups of drugs that frequently showed syn- shown in Table 4. Although indifference was the ergism or antagonism, and these combinations were subjected to quantitative evaluation on several strains, most common outcome, synergism and antago- using the checkerboard technique. Combinations nism occurred in 16.9 and 15.1% of the combi- which rarely showed synergism or antagonism were nations, respectively. not chosen for quantitative analysis. Box titrations The highest frequency of synergistic combi- were performed, with doubling dilutions in Trypticase nations was seen with mitomycin C (39%) and soy broth of the antimicrobial drug, the antineoplastic dactinomycin (35%). Antagonism was most fre- antibiotic, and every combination of each dilution of each agent. An inoculum of 0.05 ml of a 1:100 dilution of an overnight culture was added to each tube to give TABLE 2. Qualitative anti-staphylococcal activity of a final concentration of 10' to 10' organisms per ml. the antineoplastic antibiotics as determined by the Minimum inhibitory concentrations were read after cellophane transfer technique incubation at 37°C ovemight. Quantitative subcul- No. of strains tures were made of those tubes not showing growth Activity on no. of strainLs indicated ADa MC DN DX B MT by plating 0.01 ml on DST agar supplemented with 2% whole blood. Colonies were counted, and MBCs Inactive 0 0 0 0 3 1 (99.9% kill) were recorded after overnight incubation Bacteriostatic 10 0 2 7 7 9 of the plates at 37°C. Bactericidal 0 10 8 3 0 0 Fractional bactericidal concentrations (FBC) of each drug were calculated
Recommended publications
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • Antibiotic Use in Pregnancy and Lactation What Is and Is Not Known About Teratogenic and Toxic Risks
    Reviews Antibiotic Use in Pregnancy and Lactation What Is and Is Not Known About Teratogenic and Toxic Risks Gerard G. Nahum, MD, CAPT Kathleen Uhl, USPHS, and CAPT Dianne L. Kennedy, USPHS OBJECTIVE: Over ten million women are either pregnant icol, ciprofloxacin, doxycycline, levofloxacin, and or lactating in the United States at any time. The risks of rifampin) to “undetermined” (clindamycin, gentamicin, medication use for these women are unique. In addition and vancomycin). Assessments were based on “good to normal physiologic changes that alter the pharmaco- data” (penicillin G and VK), “fair data” (amoxicillin, chlor- kinetics of drugs, there is the concern of possible terato- amphenicol, ciprofloxacin, doxycycline, levofloxacin, and genic and toxic effects on the developing fetus and rifampin), “limited data” (clindamycin and gentamicin), newborn. This article reviews the risks and pharmacoki- and “very limited data” (vancomycin). Significant phar- netic considerations for 11 broad-spectrum antibiotics macokinetic changes occurred during pregnancy for the that can be used to treat routine and life-threatening penicillins, fluoroquinolones and gentamicin, indicating infections during pregnancy and lactation. that dosage adjustments for these drugs may be neces- sary. With the exception of chloramphenicol, all of these DATA SOURCES: Information from the U.S. Food and antibiotics are considered compatible with breastfeed- Drug Administration (FDA) product labels, the Teratogen ing. Information Service, REPROTOX, Shepard’s Catalog of Teratogenic Agents, Clinical Pharmacology, and the peer- CONCLUSION: Health care professionals should con- reviewed medical literature was reviewed concerning the sider the teratogenic and toxic risk profiles of antibiotics use of 11 antibiotics in pregnant and lactating women.
    [Show full text]
  • Anticancer Drug Discovery from Microbial Sources: the Unique Mangrove Streptomycetes
    molecules Review Anticancer Drug Discovery from Microbial Sources: The Unique Mangrove Streptomycetes Jodi Woan-Fei Law 1, Lydia Ngiik-Shiew Law 2, Vengadesh Letchumanan 1 , Loh Teng-Hern Tan 1, Sunny Hei Wong 3, Kok-Gan Chan 4,5,* , Nurul-Syakima Ab Mutalib 6,* and Learn-Han Lee 1,* 1 Novel Bacteria and Drug Discovery (NBDD) Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia; [email protected] (J.W.-F.L.); [email protected] (V.L.); [email protected] (L.T.-H.T.) 2 Monash Credentialed Pharmacy Clinical Educator, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia; [email protected] 3 Li Ka Shing Institute of Health Sciences, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, China; [email protected] 4 Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia 5 International Genome Centre, Jiangsu University, Zhenjiang 212013, China 6 UKM Medical Molecular Biology Institute (UMBI), UKM Medical Centre, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia * Correspondence: [email protected] (K.-G.C.); [email protected] (N.-S.A.M.); [email protected] (L.-H.L.) Academic Editor: Owen M. McDougal Received: 8 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Worldwide cancer incidence and mortality have always been a concern to the community. The cancer mortality rate has generally declined over the years; however, there is still an increased mortality rate in poorer countries that receives considerable attention from healthcare professionals.
    [Show full text]
  • Cytostatics As Hazardous Chemicals in Healthcare
    REVIEW PAPER International Journal of Occupational Medicine and Environmental Health 2019;32(2):141 – 159 https://doi.org/10.13075/ijomeh.1896.01248 CYTOSTATICS AS HAZARDOUS CHEMICALS IN HEALTHCARE WORKERS’ ENVIRONMENT ANNA PAŁASZEWSKA-TKACZ, SŁAWOMIR CZERCZAK, KATARZYNA KONIECZKO, and MAŁGORZATA KUPCZEWSKA-DOBECKA Nofer Institute of Occupational Medicine, Łódź, Poland Department of Chemical Safety Abstract Cytostatics not only induce significant side-effects in patients treated oncologically but also pose a threat to the health of occupationally exposed healthcare workers: pharmacists, physicians, nurses and other personnel. Since the 1970s numerous reports from various countries have documented the contamination of working areas with cytostatics and the presence of drugs/metabolites in the urine or blood of healthcare employees, which di- rectly indicates the occurrence of occupational exposure to these drugs. In Poland the significant scale of occupational exposure to cytostatics is also confirmed by the data collected in the central register of occupational carcinogens/mutagens kept by the Nofer Institute of Occupational Medicine. The assessment of occupational exposure to cytostatics and health risks constitutes employers’ obligation. Unfortunately, the assessment of occu- pational risk resulting from exposure to cytostatics raises a number of concerns. Provisions governing the problem of workers’ health protection are not unequivocal because they derive from a variety of law areas, especially in a matter of hazard classification and safety data sheets for cytostatics. Moreover, no legally binding occupational exposure limits have been set for cytostatics or their active compounds, and analytical methods for these substances airborne and biological concentrations are lacking. Consequently, the correct assessment of occupational exposure to cytostatics, the eval- uation of health hazards and the development of the proper preventive strategy appear difficult.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Stability of Neomycinresistance in Staphylococcus Aureus
    J. clin. Path., 1970, 23, 19-23 Stability of neomycin resistance in J Clin Pathol: first published as 10.1136/jcp.23.1.19 on 1 February 1970. Downloaded from Staphylococcus aureus G. A. J. AYLIFFE From the Hospital Infection Research Laboratory, Summerfield Hospital, Birmingham SYNOPSIS A strain of Staphylococcus aureus isolated from the skin of a subject with eczema showed a loss in resistance to neomycin and tetracycline after treatment with neomycin was stopped. Seven out of 22 strains of neomycin-resistant Staph. aureus showed a loss in resistance to neomycin and streptomycin after storage in nutrient broth for 14 days at room temperature, and it seems probable that resistance in these unstable strains was controlled by extra- chromosomal elements or plasmids. Strains of phage types 84/85 and 29/77 and related types were frequently isolated in general hospital wards and showed no loss in resistance on similarcopyright. storage in nutrient broth. Five of the neomycin-unstable strains were isolated frompatientswith eczematous lesions. Multiple-resistant and antibiotic-sensitive strains ofStaph.aureus of similar phage type were isolated from patients in a ward for patients with skin disease, and the pos- sibility oftransfer ofresistance in vivo is discussed. http://jcp.bmj.com/ The selection of neomycin-resistant strains of In the present study, changes in resistance to on September 30, 2021 by guest. Protected Staph. aureus by neomycin or related compounds antibiotics of Staph. aureus isolated from the and the disappearance after discontinuing the eczematous subject after discontinuing treatment use of these antibiotics has been shown in a with neomycin were investigated.
    [Show full text]
  • Persistent Gestational Trophoblastic Disease Is Potentially Fatal, but the Majority of Patients Are Cured with Chemotherapy
    British Journal of Cancer (2000) 82(9), 1547–1552 © 2000 Cancer Research Campaign DOI: 10.1054/ bjoc.2000.1176, available online at http://www.idealibrary.com on Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease LS Dobson, PC Lorigan, RE Coleman and BW Hancock Gestational Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK Summary Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis.
    [Show full text]
  • A Genome-Wide Screen in Saccharomyces Cerevisiae Reveals a Critical Role for the Mitochondria in the Toxicity of a Trichothecene Mycotoxin
    A genome-wide screen in Saccharomyces cerevisiae reveals a critical role for the mitochondria in the toxicity of a trichothecene mycotoxin John E. McLaughlina,1, Mohamed Anwar Bin-Umera,1, Andrew Tortoraa, Natasha Mendeza, Susan McCormickb, and Nilgun E. Tumera,2 aBiotechnology Center for Agriculture and the Environment and the Department of Plant Biology and Pathology, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ, 08901-8520; and bMycotoxin Research Unit, National Center for Agricultural Utilization Research, United States Department of Agriculture, Agricultural Research Service, Peoria, IL, 61604 Edited by Joan Wennstrom Bennett, Rutgers University, New Brunswick, NJ; and approved October 19, 2009 (received for review August 27, 2009) Trichothecene mycotoxins synthesized by Fusarium species are transferase center in Saccharomyces cerevisiae and inhibit potent inhibitors of eukaryotic translation. They are encountered peptidyltransferase activity of eukaryotic ribosomes (7–9). in both the environment and in food, posing a threat to human and Trichodermin-resistant yeast mutants were also resistant to animal health. They have diverse roles in the cell that are not anisomycin (9) and the trichodermin binding site on the 60S limited to the inhibition of protein synthesis. To understand the ribosomal subunit was closely related to the binding site of trichothecene mechanism of action, we screened the yeast knock- anisomycin (9, 10). out library to identify genes whose deletion confers resistance to Trichothecenes and translation inhibitors like anisomycin that trichothecin (Tcin). The largest group of resistant strains affected target the peptidyltransferase center are known to induce the mitochondrial function, suggesting a role for fully active mitochon- ribotoxic stress response that leads to rapid activation of mitogen dria in trichothecene toxicity.
    [Show full text]
  • Dactinomycin
    Dactinomycin DRUG NAME: Dactinomycin 1 SYNONYM(S) : actinomycin D, actinomycin C1 COMMON TRADE NAME(S): COSMEGEN® CLASSIFICATION: antitumour antibiotic Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Dactinomycin is an antineoplastic antibiotic derived from Streptomyces parvullus.2 Stable complexes are formed with DNA through intercalation and DNA-dependent RNA synthesis is selectively inhibited.1-3 Protein and DNA synthesis are inhibited to a lesser extent.3 Dactinomycin is cell cycle phase-nonspecific1. Dactinomycin is an immunosuppressive agent.3 PHARMACOKINETICS: Oral Absorption poor3 Distribution rapid; high concentrations in bone marrow and nucleated cells3; extensively bound to body tissues cross blood brain barrier? <10% volume of distribution no information found plasma protein binding not highly protein bound Metabolism minimal active metabolite(s) none inactive metabolite(s)3 small amounts of monolactones have been recovered in urine Excretion rapidly cleared from plasma (85% within 2 min) urine 12-20% of dose recovered within 24 h, 15% of dose recovered unchanged after 1 week feces 50-90% of dose excreted in bile within 24 h, 15% of dose recovered after 1 week terminal half life 36 hours, possibly prolonged with hepatic dysfunction clearance no information found Adapted from standard reference2 unless specified otherwise. USES: Primary uses: Other uses: *Gestational trophoblastic tumour *Ewing’s sarcoma *Rhabdomyosarcoma Ovarian germ cell tumour3 *Wilms’ tumour Kaposi’s sarcoma4 5 Malignant melanoma 3,6 Testicular cancer *Health Canada approved indication BC Cancer Drug Manual© All rights reserved. Page 1 of 8 Dactinomycin This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy.
    [Show full text]
  • Dactinomycin for INJECTION, USP
    Dactinomycin FOR INJECTION, USP 10 DIGIT NDC STRENGTH SIZE WHOLESALE NUMBERS WEB LISTING 39822-2100-2 ABC 10229241 500 mcg 1 Cardinal 5557707 11 DIGIT NDC (0.5 mg) per vial vial McKesson 3975687 39822-2100-02 Morris Dickson 772301 OTHER INFORMATION PRESERVATIVE FREE LATEX FREE STOPPER CONTROLLED ROOM TEMPERATURE STORAGE - - - BARCODED FOR PATIENT SAFETY Dactinomycin FOR INJECTION, USP HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use • Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: Dactinomycin for Injection safely and effectively. See full prescribing • Lower Extremity or Pelvis: The recommend dose is 50 mcg/kg once with information for Dactinomycin for Injection. melphalan. (2.6) ◦ Upper Extremity: The recommended dose is 35 mcg/kg once with melphalan. (2.6) Dactinomycin for Injection for intravenous use Initial U.S. Approval: 1964 DOSAGE FORMS AND STRENGTHS For injection: 500 mcg as a lyophilized powder in a single-dose vial. (3) RECENT MAJOR CHANGES • Dosage and Administration, Recommended Dosage for Wilms Tumor (2.1) CONTRAINDICATIONS 8/2018 None. (4) • Dosage and Administration, Recommended Dosage for Ewing Sarcoma (2.3) 8/2018 WARNINGS AND PRECAUTIONS • Secondary Malignancy or Leukemia: Increased risk of secondary malignancies INDICATIONS AND USAGE following treatment. (5.1) Dactinomycin for injection is an actinomycin indicated for the treatment of: • Veno-occlusive Disease: Can cause severe or fatal VOD. Monitor for elevations in • adult and pediatric patients with Wilms tumor, as part of a multi-phase, AST, ALT, total bilirubin, hepatomegaly, weight gain, or ascites. Consider delaying combination chemotherapy regimen. (1.1) next dose.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Process for Producing Arsenic Trioxide Formulations
    (19) TZZ_964557B_T (11) EP 1 964 557 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/285 (2006.01) A61K 33/36 (2006.01) 02.01.2013 Bulletin 2013/01 A61P 35/02 (2006.01) (21) Application number: 08075200.9 (22) Date of filing: 10.11.1998 (54) Process for producing arsenic trioxide formulations Verfahren zur Herstellung von Arsentrioxidformulierungen Procédé de production de formulations à base de trioxide d’arsenic (84) Designated Contracting States: (74) Representative: Warner, James Alexander et al AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Carpmaels & Ransford MC NL PT SE One Southampton Row London (30) Priority: 10.11.1997 US 64655 P WC1B 5HA (GB) (43) Date of publication of application: (56) References cited: 03.09.2008 Bulletin 2008/36 • KWONG Y L ET AL: "Delicious poison: Arsenic trioxide for the treatment of leukemia" BLOOD, (60) Divisional application: vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 10177319.0 / 2 255 800 3487-3488, XP002195910 • SHEN S-X ET AL: "USE OF ARSENIC TRIOXIDE (62) Document number(s) of the earlier application(s) in (AS2O3) IN THE TREATMENT OF ACUTE accordance with Art. 76 EPC: PROMYELOCITIC LEUKEMIA (APL): II. CLINICAL 98957803.4 / 1 037 625 EFFICACY AND PHARMACOKINETICS IN RELAPSED PATIENTS" BLOOD, W.B. (73) Proprietor: MEMORIAL SLOAN-KETTERING SAUNDERS, PHILADELPHIA, VA, US, vol. 89, no. CANCER CENTER 9, 1 May 1997 (1997-05-01), pages 3354-3360, New York, NY 10021 (US) XP000891715 ISSN: 0006-4971 • KONIG ET AL: "Comparative activity of (72) Inventors: melarsoprol and arsenic trioxide in chronic B - • Warrell, Raymond, P., Jr.
    [Show full text]